The Patent Finder
HL

H. Lundbeck A/S

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

249 patents currently held

11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
38
Ending by 2030
Dec 2026
Next term end
120
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 18, 2026
    The maintenance fee for Pyrazole Compounds and Methods of Making and Using Same (US 10,323,038) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
  • 11 fees due Jan 2 to 30, 2027 · next Jan 2
  • 5 fees due Feb 13 to 28, 2027 · next Feb 13
  • 2 fees due Mar 15, 2027
  • 2 fees due Apr 1 to 10, 2027 · next Apr 1
  • 7 fees due May 5 to 28, 2027 · next May 5
  • 8 fees due Jun 10 to 30, 2027 · next Jun 10
  • 6 fees due Jul 2 to 28, 2027 · next Jul 2
  • 3 fees due Aug 4 to 18, 2027 · next Aug 4
  • 3 fees due Sep 8 to 26, 2027 · next Sep 8
  • 6 fees due Oct 12 to 28, 2027 · next Oct 12
  • 4 fees due Nov 5 to 12, 2027 · next Nov 5

Which patents, and when each one lapses · Pro

Recent changes

  • Oct 13Assignment recorded on 1 record: Juhl, Karsten and 10 others to H. Lundbeck A/S Recorded Oct 13, 2026, executed Mar 20, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76355, frame 76.
  • 2 of the patents on this record were granted since Aug 18, 2026
  • 3 terms have ended since Aug 18, 2026

What they patent

The 5 largest of its 120 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 7,544,685Novel 2,3-Dihydroindole Compounds
In force
 · High confidence
In forceHigh confidence
US 8,022,084Polymorphic Forms of a Gabaa Agonist
In force
 · High confidence
In forceHigh confidence
US 8,969,3551-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · High confidence
In forceHigh confidence
US 9,095,588Process for Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-PHENY]PIPERAZINE or Pharmaceutically Acceptable Salt Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,101,626Process For Preparing 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine Or Pharmaceutically Acceptable Salt Thereof
In force
 · High confidence
In forceHigh confidence
US 9,125,9081-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · High confidence
In forceHigh confidence
US 9,125,9091-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · Medium confidence
In forceMedium confidence
US 9,125,9101-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · Medium confidence
In forceMedium confidence
US 9,227,9461-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment
In force
 · High confidence
In forceHigh confidence
US 9,744,166Therapeutic Uses of Compounds Having Combined SERT, 5-HT3 and 5-HT1A Activity
In force
 · Medium confidence
In forceMedium confidence
10 of 249 patents shown.
Pro members see all 249.
Pro members: see all 249 patents
Also on record, not counted in the 249: 11 patents in force now held by others · 315 patents ended · 35 applications pending · 267 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited